Revolution Medicines Begins Phase 3 Trial For Advanced Lung Cancer Treatment

What happened: Revolution Medicines Inc. (NASDAQ:RVMD) began treating patients in its global Phase 3 study, RASolve 308, testing zoldonrasib with standard care as first-line treatment for adults with non-squamous non-small cell lung cancer harboring the RAS G12D mutation. Key numbers: Trial compares zoldonrasib plus pembrolizumab and platinum-based chemotherapy against placebo with the same regimen. Why it matters: The Phase 3 start advances zoldonrasib toward a potential first-line combination use in RAS G12D mutant lung cancer, and shares rose on the news. Market: +7.3% today ($195.48), +147.4% YTD, 0.8x vol — as of 18:47 UTC

Revolution Medicines Inc. (NASDAQ:RVMD) began treating patients in its global Phase 3 study, RASolve 308, testing zoldonrasib with standard care as first-line treatment for adults with non-squamous non-small cell lung cancer harboring the RAS G12D mutation.

The Phase 3 start advances zoldonrasib toward a potential first-line combination use in RAS G12D mutant lung cancer, and shares rose on the news. Market: +7.3% today ($195.48), +147.4% YTD, 0.8x vol — as of 18:47 UTC